Novartis, Incyte to testruxolitinib for use in Covid-19 associated cytokine storm

Sharing is Caring!

by TurquoiseRose,_incyte_to_test_jakavi_for_coronavirus-linked_cytokine_storm_1335533

Novartis and Incyte are planning to launch a clinical study to test the potential of Jakavi (ruxolitinib) in patients with COVID-19 associated cytokine storm, a type of severe immune overreaction that can result from the infection and may contribute to respiratory compromise in some patients.

According to the Swiss drugmaker, preclinical and preliminary clinical evidence suggests that the JAK inhibitor could reduce the number of patients requiring intensive care and mechanical ventilation.

Phase III Trial

Research referenced in the above article.

COVID-19: consider cytokine storm syndromes and immunosuppression

Cytokine storm



Disclaimer: This is a guest post and it doesn’t represent the views of IWB.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.